[go: up one dir, main page]

AR128846A1 - Compuestos de indazol sustituidos con piperazina como inhibidores de parg - Google Patents

Compuestos de indazol sustituidos con piperazina como inhibidores de parg

Info

Publication number
AR128846A1
AR128846A1 ARP230100697A ARP230100697A AR128846A1 AR 128846 A1 AR128846 A1 AR 128846A1 AR P230100697 A ARP230100697 A AR P230100697A AR P230100697 A ARP230100697 A AR P230100697A AR 128846 A1 AR128846 A1 AR 128846A1
Authority
AR
Argentina
Prior art keywords
indazole compounds
substituted indazole
piperazine substituted
parg inhibitors
parg
Prior art date
Application number
ARP230100697A
Other languages
English (en)
Inventor
Paul A Barsanti
Michael Patrick Dillon
Firoz Ali Jaipuri
Ying Xu
- Linghu Xin Zi
Monah Abed
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of AR128846A1 publication Critical patent/AR128846A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en el presente documento compuestos de fórmula (1) o una sal farmacéuticamente aceptable de este. Los compuestos proporcionados son inhibidores útiles de la poli(ADPribosa)glicohidrolasa (PARG). Se describen otras utilidades y ventajas en el presente documento.
ARP230100697A 2022-03-23 2023-03-22 Compuestos de indazol sustituidos con piperazina como inhibidores de parg AR128846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263322994P 2022-03-23 2022-03-23

Publications (1)

Publication Number Publication Date
AR128846A1 true AR128846A1 (es) 2024-06-19

Family

ID=86053625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100697A AR128846A1 (es) 2022-03-23 2023-03-22 Compuestos de indazol sustituidos con piperazina como inhibidores de parg

Country Status (17)

Country Link
US (2) US12269820B2 (es)
EP (1) EP4496795A1 (es)
JP (1) JP7783436B2 (es)
KR (1) KR20240165402A (es)
CN (1) CN119255994A (es)
AR (1) AR128846A1 (es)
AU (1) AU2023239344A1 (es)
CA (1) CA3245542A1 (es)
CL (1) CL2024002805A1 (es)
CO (1) CO2024012798A2 (es)
CR (1) CR20240391A (es)
DO (1) DOP2024000187A (es)
IL (1) IL315722A (es)
MX (1) MX2024011545A (es)
PE (1) PE20251690A1 (es)
TW (1) TW202345809A (es)
WO (1) WO2023183850A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
AU2020348489A1 (en) * 2019-09-20 2022-05-05 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as PARG inhibitors
AU2023239344A1 (en) 2022-03-23 2024-10-10 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg
CN121335701A (zh) * 2023-04-05 2026-01-13 艾迪亚生物科学公司 用于治疗癌症的包含parg抑制剂和拓扑异构酶抑制剂的联合疗法
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025064750A1 (en) * 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
TW202528308A (zh) * 2023-09-20 2025-07-16 美商愛德亞生物科學公司 Parg抑制劑
WO2025082231A1 (zh) * 2023-10-20 2025-04-24 上海璎黎药业有限公司 一种杂芳环磺酰胺结构化合物、其药物组合物及应用
WO2025087941A1 (en) 2023-10-23 2025-05-01 Universite De Geneve Parg inhibitors in combination with parp inhibitors and uses thereof
WO2025087409A1 (zh) * 2023-10-26 2025-05-01 上海齐鲁制药研究中心有限公司 Parg抑制剂
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157858A (en) 1979-12-03 1983-11-29 Ikuo Ueda Quinazoline derivatives
DE4407047A1 (de) 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7009052B2 (en) 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
WO2007014226A2 (en) 2005-07-26 2007-02-01 The Board Of Trustees Of The University Of Illinois Compounds for the treatment of neurodegeneration and stroke
US7932284B2 (en) 2006-01-24 2011-04-26 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
CN101405001A (zh) 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 抑制btk和syk蛋白质激酶的方法
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CN101903025A (zh) 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
EP2298767A4 (en) 2008-07-17 2011-10-19 Asahi Kasei Pharma Corp NITROGENATED BICYCLIC AND HETEROCYCLIC COMPOUND
CN101429191B (zh) 2008-11-03 2012-05-23 中国药科大学 取代的四氢异喹啉衍生物的用途
EP2523559A4 (en) 2010-01-13 2013-11-06 Glaxosmithkline Llc COMPOUNDS AND METHODS
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
US20130053375A1 (en) 2010-05-07 2013-02-28 Glaxo Group Limited Amino-quinolines as kinase inhibitors
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
KR20130129244A (ko) 2010-12-17 2013-11-27 에프. 호프만-라 로슈 아게 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
EP2714688B1 (en) 2011-05-26 2016-02-24 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
EA201591220A1 (ru) 2012-12-27 2016-01-29 Дрексел Юниверсити Новые противовирусные агенты против инфекции вирусом гепатита в
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
MA46856A (fr) 2016-11-18 2019-09-25 Merck Sharp & Dohme Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
US12491188B2 (en) 2019-03-29 2025-12-09 Board Of Regents, The University Of Texas System Small molecule PARG inhibitors and methods of use thereof
AU2020348489A1 (en) 2019-09-20 2022-05-05 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as PARG inhibitors
WO2023057389A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag Parg inhibitory compounds
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CN119013261A (zh) 2022-02-14 2024-11-22 雅瑞斯医疗公司 Parg的抑制剂
US20230272485A1 (en) 2022-02-16 2023-08-31 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
AU2023239344A1 (en) 2022-03-23 2024-10-10 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg
JP2025523576A (ja) 2022-06-29 2025-07-23 杭州聖域生物医薬科技有限公司 含窒素５，６－縮合化合物、その中間体、調製方法及び用途
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2024148280A1 (en) 2023-01-06 2024-07-11 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds

Also Published As

Publication number Publication date
CR20240391A (es) 2024-11-05
JP2025512780A (ja) 2025-04-22
EP4496795A1 (en) 2025-01-29
AU2023239344A1 (en) 2024-10-10
US20250376467A1 (en) 2025-12-11
KR20240165402A (ko) 2024-11-22
US20230303556A1 (en) 2023-09-28
IL315722A (en) 2024-11-01
TW202345809A (zh) 2023-12-01
CL2024002805A1 (es) 2025-05-09
PE20251690A1 (es) 2025-07-02
CA3245542A1 (en) 2023-09-28
CN119255994A (zh) 2025-01-03
MX2024011545A (es) 2024-09-26
US12269820B2 (en) 2025-04-08
DOP2024000187A (es) 2024-12-30
WO2023183850A1 (en) 2023-09-28
JP7783436B2 (ja) 2025-12-09
CO2024012798A2 (es) 2024-10-21

Similar Documents

Publication Publication Date Title
AR128846A1 (es) Compuestos de indazol sustituidos con piperazina como inhibidores de parg
MX2022003276A (es) Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg.
PE20231207A1 (es) Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
AR116604A1 (es) Inhibidores de kras g12c
CO2024011199A2 (es) Composiciones y métodos para inhibir el factor b del complemento
MX2024010399A (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
AR132295A1 (es) Inhibidores de kras
AR132294A1 (es) Inhibidores de kras
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
CO2024010542A2 (es) Inhibidores de apol1 y métodos de uso
TR200103067T2 (tr) Renin inhibitörleri
UY40234A (es) Compuestos heteroarilo para el tratamiento del dolor
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
SV2007002526A (es) Diarilsulfona sulfonamidas y el uso de las mismas ref. p1018
AR040274A1 (es) Derivados de 1-[(indol-3-il)carbonil]piperazina como agonistas de canabinoides en el tratamiento del dolor y composiciones farmaceuticas
MX2020011367A (es) Compuesto oxo-sustituido.
CL2024000114A1 (es) Compuestos terapéuticos y procedimientos.
UY31854A (es) Derivados sustituidos de 3-oxo-isoindolin-1- carboxamidas n-sustituidas y aplicaciones
MX2023012958A (es) Compuestos y metodos anticonceptivos.
MX2022016516A (es) Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.
UY29979A1 (es) Derivados espirociclicos
AR125350A1 (es) Inhibidores tead
MX2010010561A (es) Derivados tiazol de benzofenona utiles para inhibir la formacion del microtúbulo, y método para producir los mismos.